M Schafers
Overview
Explore the profile of M Schafers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
88
Citations
1032
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Backhaus P, Gierse F, Burg M, Buther F, Asmus I, Dorten P, et al.
Eur J Nucl Med Mol Imaging
. 2021 Dec;
49(6):1822-1832.
PMID: 34957527
Purpose: The fibroblast activation protein (FAP) is an emerging target for molecular imaging and therapy in cancer. OncoFAP is a novel small organic ligand for FAP with very high affinity....
2.
3.
Kurch L, Hasenclever D, Kluge R, Georgi T, Tchavdarova L, Golombeck M, et al.
Pediatr Blood Cancer
. 2018 Nov;
66(3):e27539.
PMID: 30426671
Purpose: In 2014, we published the qPET method to quantify fluorodeoxyglucose positron emission tomography (FDG-PET) responses. Analysis of the distribution of the quantified signals suggested that a clearly abnormal FDG-PET...
4.
Oertel M, Scobioala S, Kroeger K, Baehr A, Stegger L, Haverkamp U, et al.
Radiat Oncol
. 2018 Sep;
13(1):185.
PMID: 30241556
Background: Prostate cancer (PCA) is the most-prevalent non-skin cancer in men worldwide. Nevertheless, the treatment of oligometastatic, especially lymph-node (ln) recurrent, PCA remains elusive. The aim of our study was...
5.
Ahmadzadehfar H, Albers P, Bockisch A, Boegemann M, Bohme C, Burchert W, et al.
Urologe A
. 2018 Apr;
57(6):709-713.
PMID: 29671080
In the last 3 years, Lutetium-177 prostate-specific membrane antigen radioligand therapy (Lu-177-PSMA-RLT) has received increasing attention in nuclear medicine as a new form of treatment for castration-resistant metastatic prostate cancer....
6.
Kurth J, Krause B, Schwarzenbock S, Stegger L, Schafers M, Rahbar K
EJNMMI Res
. 2018 Apr;
8(1):32.
PMID: 29651569
Background: Prostate-specific membrane antigen (PSMA)-targeted therapy with Lu-PSMA-617 is a therapeutic option for patients with metastatic castration-resistant prostate cancer (mCRPC). To optimize the therapy procedure, it is necessary to determine...
7.
Rahbar K, Boegemann M, Yordanova A, Eveslage M, Schafers M, Essler M, et al.
Eur J Nucl Med Mol Imaging
. 2017 Oct;
45(1):12-19.
PMID: 29026946
Aim: Our aim was to evaluate overall survival and parameters prognosticating longer survival in a large and homogeneous group of patients treated with Lu-PSMA-617 radioligand therapy with heavily pretreated advanced...
8.
Leo M, Schulte M, Schmitt L, Schafers M, Kleinschnitz C, Hagenacker T
Mediators Inflamm
. 2017 Aug;
2017:2786427.
PMID: 28831207
Transient receptor potential vanilloid-1 (TRPV1) is a nonselective cation channel, predominantly expressed in sensory neurons. TRPV1 is known to play an important role in the pathogenesis of inflammatory and neuropathic...
9.
Bailey D, Pichler B, Guckel B, Barthel H, Beer A, Botnar R, et al.
Mol Imaging Biol
. 2016 Aug;
18(5):637-50.
PMID: 27534971
This article provides a collaborative perspective of the discussions and conclusions from the fifth international workshop of combined positron emission tomorgraphy (PET)/magnetic resonance imaging (MRI) that was held in Tübingen,...
10.
Hansen T, Weckesser M, Schafers M, Gunnemann A
Urologe A
. 2016 Jun;
56(1):50-53.
PMID: 27272004
We report on the case of an 81-year-old man suffering from prostate cancer for several years. In recent months, PSA levels increased, and Ga-PSMA-PET-CT (PSMA: prostate-specific membrane antigen) imaging demonstrated...